Fin 534 Week 9 Assignment 1 Financial Research Report

Financial Research Report: ACADIA Pharmaceutical Inc.Student NameInstructorCourseDateTable of contents TOC \o "1-2" \h \z \u 1.0 Introduction PAGEREF _Toc413823607 \h 32.0 Rationale for choosing this company for investment PAGEREF _Toc413823608 \h 33.0 Ratio analysis PAGEREF _Toc413823609 \h 43.1 Liquidity ratios PAGEREF _Toc413823610 \h 53.2 Leverage/solvency ratios PAGEREF _Toc413823611 \h 73.3 Efficiency ratios PAGEREF _Toc413823612 \h 83.4 Profitability ratios PAGEREF _Toc413823613 \h 94.0 Risk concentration PAGEREF _Toc413823614 \h 105.0 Stock price analysis PAGEREF _Toc413823615 \h 116.0 Recommendations PAGEREF _Toc413823616 \h 13References PAGEREF _Toc413823617 \h 141.0 IntroductionThis biopharmaceutical organization is based on innovative small molecule drugs that address unmet medical requirements in neurological and other disorders of the related central nervous system. The company owns a pipeline of product candidates that is led by pimavanserin that is in phase III development regarded as potential first-in-class treatment for various diseases such as the Parkinson’s disease psychosis. Recently, the company reported successful top-line outcomes from a pivotal phase III pimavanserin trial in patients experiencing Parkinson’s disease psychosis. The organization possesses a globally commercialization rights concerning pimavanserin. The